CAMBRIDGE, Mass., Feb. 10 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) will announce its fourth quarter and year-end
2004 financial results on February 23, 2005 before the open of U.S. financial
markets. In connection with this announcement, TKT will host a conference call
and live audio webcast on February 23, 2005 at 10:00 a.m. Eastern Time to
discuss its fourth quarter and full year 2004 financial results and financial
outlook for 2005.
Participants may access the call by dialing (913) 981-5533. This call will
also be broadcast live over the Internet at http://www.tktx.com under the
Investor Information section. Please dial in 5 to 10 minutes prior to the
scheduled conference call time or log on to the website at least 15 minutes
prior to the call in order to register, download, and install any necessary
software.
A replay of this conference call will be available for two weeks,
beginning February 23, 2005 at 1:00 p.m. Eastern Time by dialing (719) 457-
0820 and using the access code 6847230. In addition, a replay of the webcast
will be archived on the TKT website under Events in the Investor Information
section.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily
focused on researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the company
markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and South America.
Additional information about TKT is available on the company's website at
http://www.tktx.com.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of
Sanofi-Aventis SA.
For More Information Contact:
Daniella M. Lutz
Corporate Communications Manager
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Daniella M. Lutz, Corporate Communications
Manager of Transkaryotic Therapies, Inc., +1-617-349-0205
|
